Chemical and biological evaluations of an (111)in-labeled RGD-peptide targeting integrin alpha(V) beta(3) in a preclinical tumor model.
about
A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung CancerBiodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.RAM, an RGDS analog, exerts potent anti-melanoma effects in vitro and in vivo.Lymphatic imaging: focus on imaging probes.Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in miceTargeted delivery of a proapoptotic peptide to tumors in vivo.Positron emission tomography imaging of tumor angiogenesis and monitoring of antiangiogenic efficacy using the novel tetrameric peptide probe 64Cu-cyclam-RAFT-c(-RGDfK-)4.68Ga-NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer.Targeted radionuclide therapy with RAFT-RGD radiolabelled with (90)Y or (177)Lu in a mouse model of αvβ3-expressing tumours.Comparison of three dimeric 18F-AlF-NOTA-RGD tracers.Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin αvβ3 targeting using single photon emission computed tomography and optical imaging.αvβ3 imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical study.
P2860
Q33767056-64F7663D-9D34-4C04-870C-8F364994F2DCQ33836864-3B98EEE8-4849-41EA-8369-D2D602CE3A34Q34044872-ABAF29B5-857E-47A4-A4D5-FFBFEFEE846EQ35475925-E8E600B6-D681-444B-A4C6-CF49B7F6356AQ35629161-D346013B-C62B-447D-900F-C1B9C0EF791DQ35884337-394A618A-B2AF-4D0E-98CE-5CAB33D5E3CFQ36394255-2EDC987D-3AFC-43B2-BB96-6BBA5CBC20B5Q37575733-2FA1DC3A-4E39-46C8-B274-38719B07AC7DQ38962269-BA55667E-BB78-44A8-95B5-240AE86B916AQ39104091-FD2F6FE5-D628-484E-8EC5-21A2FBB4475DQ39373913-A4569F8F-AB2F-4619-A137-C15F1ADEB7E8Q39649778-C7DA8E55-3DEC-48C7-BC2B-8D6951B5328E
P2860
Chemical and biological evaluations of an (111)in-labeled RGD-peptide targeting integrin alpha(V) beta(3) in a preclinical tumor model.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Chemical and biological evalua ...... in a preclinical tumor model.
@en
Chemical and biological evaluations of an
@nl
type
label
Chemical and biological evalua ...... in a preclinical tumor model.
@en
Chemical and biological evaluations of an
@nl
prefLabel
Chemical and biological evalua ...... in a preclinical tumor model.
@en
Chemical and biological evaluations of an
@nl
P2093
P50
P356
P1476
Chemical and biological evalua ...... ) in a preclinical tumor model
@en
P2093
Catherine Ghezzi
Daniel Fagret
Jean-Philippe Vuillez
P304
P356
10.1089/CBR.2008.0528
P577
2008-12-01T00:00:00Z